Open-Angle Glaucoma - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 89 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Open-Angle Glaucoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Open-Angle Glaucoma - Pipeline Review, H2 2014', provides an overview of the Open-Angle Glaucoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Open-Angle Glaucoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Open-Angle Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Open-Angle Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Open-Angle Glaucoma Overview 9
Therapeutics Development 10
Pipeline Products for Open-Angle Glaucoma - Overview 10
Pipeline Products for Open-Angle Glaucoma - Comparative Analysis 11
Open-Angle Glaucoma - Therapeutics under Development by Companies 12
Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes 14
Open-Angle Glaucoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Open-Angle Glaucoma - Products under Development by Companies 18
Open-Angle Glaucoma - Products under Investigation by Universities/Institutes 19
Open-Angle Glaucoma - Companies Involved in Therapeutics Development 20
F. Hoffmann-La Roche Ltd. 20
Bausch & Lomb Incorporated 21
Santen Pharmaceutical Co., Ltd. 22
Oxford BioMedica plc 23
Sylentis S.A. 24
Ono Pharmaceutical Co., Ltd. 25
Asahi Kasei Pharma Corp. 26
Inotek Pharmaceuticals Corporation 27
Aerie Pharmaceuticals, Inc. 28
Otsuka Holdings Co., Ltd. 29
Amakem NV 30
Open-Angle Glaucoma - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Target 33
Assessment by Mechanism of Action 36
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
tafluprost - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(tafluprost + timolol maleate) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
latanoprostene bunod - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
latanoprost - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OPC-1085EL - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
trabodenoson - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
SYL-040012 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
RO-5093151 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
latanoprost - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AR-13324 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AMA-0076 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ONO-9054 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
ATS-907 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
DE-117 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
(latanoprost + dorzolamide) - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LX-7101 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HPP-851 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OPA-6566 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
latanoprost SR - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Glaucoma-GT - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ATS-8535 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecule for Glaucoma - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Open-Angle Glaucoma - Recent Pipeline Updates 70
Open-Angle Glaucoma - Dormant Projects 80
Open-Angle Glaucoma - Discontinued Products 81
Open-Angle Glaucoma - Product Development Milestones 82
Featured News & Press Releases 82
Jan 13, 2014: Forest Laboratories Pursues Additional Market Exclusivity to Extend Namenda Patent 82
Dec 12, 2012: Sucampo Pharma Receives FDA Approval Of sNDA For Rescula 82
May 01, 2012: Quark To Initiate Phase IIa Study Of PF-655 In Patients With Moderate And Advanced Open-Angle Glaucoma 82
Mar 13, 2012: NicOx, Bausch + Lomb's Glaucoma Candidate BOL-303259-X Meets Primary Endpoint In Phase IIb Study 83
Feb 13, 2012: FDA Approves Merck's ZIOPTAN For Treatment Of Intraocular Pressure In Glaucoma Patients 84
Nov 28, 2011: NicOx Announces Completion Of Patient Recruitment In Glaucoma Study 85
Sep 26, 2011: Clermont Reports Positive Phase III Results For Non-Preserved Latanoprost To Treat Glaucoma 85
May 06, 2010: R-Tech Ueno's Sanda Factory Gets U.S. Nod for Manufacture of Rescula Eye Drops. 85
Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System 86
Mar 04, 2010: Frost & Sullivan Recognizes Timoptic as Best Brand Name Beta Blocker for Glaucoma 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89

List of Tables
Number of Products under Development for Open-Angle Glaucoma, H2 2014 10
Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 19
Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 20
Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2014 21
Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2014 22
Open-Angle Glaucoma - Pipeline by Oxford BioMedica plc, H2 2014 23
Open-Angle Glaucoma - Pipeline by Sylentis S.A., H2 2014 24
Open-Angle Glaucoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 25
Open-Angle Glaucoma - Pipeline by Asahi Kasei Pharma Corp., H2 2014 26
Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2014 27
Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2014 28
Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 29
Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Assessment by Combination Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 35
Number of Products by Stage and Mechanism of Action, H2 2014 38
Number of Products by Stage and Route of Administration, H2 2014 40
Number of Products by Stage and Molecule Type, H2 2014 42
Open-Angle Glaucoma Therapeutics - Recent Pipeline Updates, H2 2014 70
Open-Angle Glaucoma - Dormant Projects, H2 2014 80
Open-Angle Glaucoma - Discontinued Products, H2 2014 81